Axillary Hyperhidrosis - Pipeline Review, H2 2020
Axillary Hyperhidrosis - Pipeline Review, H2 2020
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Axillary Hyperhidrosis - Pipeline Review, H2 2020, provides an overview of the Axillary Hyperhidrosis (Dermatology) pipeline landscape.
Axillary hyperhidrosis also referred to as excessive underarm sweating. Excessive sweating in the affected area is caused by over activity of the nerves linked to the sweat glands. Specifically, acetylcholine, a chemical in the body that transmits nerve signals, is released from nerve endings and stimulates secretion of sweat. The condition most frequently develops in adolescence or young adulthood. Treatment includes anticholinergic drugs, surgery and antiperspirants.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Axillary Hyperhidrosis - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Axillary Hyperhidrosis (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Axillary Hyperhidrosis (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Axillary Hyperhidrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 3, 1, 1 and 2 respectively.
Axillary Hyperhidrosis (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note:
Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Axillary Hyperhidrosis - Pipeline Review, H2 2020, provides an overview of the Axillary Hyperhidrosis (Dermatology) pipeline landscape.
Axillary hyperhidrosis also referred to as excessive underarm sweating. Excessive sweating in the affected area is caused by over activity of the nerves linked to the sweat glands. Specifically, acetylcholine, a chemical in the body that transmits nerve signals, is released from nerve endings and stimulates secretion of sweat. The condition most frequently develops in adolescence or young adulthood. Treatment includes anticholinergic drugs, surgery and antiperspirants.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Axillary Hyperhidrosis - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Axillary Hyperhidrosis (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Axillary Hyperhidrosis (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Axillary Hyperhidrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 3, 1, 1 and 2 respectively.
Axillary Hyperhidrosis (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note:
Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Axillary Hyperhidrosis (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Axillary Hyperhidrosis (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Axillary Hyperhidrosis (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Axillary Hyperhidrosis (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Axillary Hyperhidrosis (Dermatology)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Axillary Hyperhidrosis (Dermatology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Axillary Hyperhidrosis (Dermatology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Axillary Hyperhidrosis - Overview
Axillary Hyperhidrosis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Axillary Hyperhidrosis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Axillary Hyperhidrosis - Companies Involved in Therapeutics Development
Brickell Biotech Inc
DelNova Inc
Dermata Therapeutics LLC
Dermavant Sciences Inc
Dermira Inc
Dr. August Wolff GmbH & Co KG Arzneimittel
Medytox Inc
Revance Therapeutics Inc
Axillary Hyperhidrosis - Drug Profiles
(oxybutynin + pilocarpine) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DMT-410 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
glycopyrrolate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
glycopyrronium tosylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nivobotulinumtoxin A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
onabotulinumtoxinA biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ReViVox - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sofpironium bromide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Axillary Hyperhidrosis - Dormant Projects
Axillary Hyperhidrosis - Discontinued Products
Axillary Hyperhidrosis - Product Development Milestones
Featured News & Press Releases
Aug 31, 2020: Brickell Biotech announces issuance of new composition of matter patent on Sofpironium Bromide by the Japanese Patent Office
Jun 15, 2020: Confirmatory phase 3 study of BBI-4000 meet primary endpoint- Announcement at the 119th Annual Meeting of the Japanese Dermatological Association and the 2020 Annual Meeting of American Academy of Dermatology
Jun 15, 2020: Brickell Biotech announces positive Phase 3 pivotal study results for Sofpironium Bromide in Japan released by development partner, Kaken Pharmaceutical
Mar 04, 2020: Brickell Biotech announces late-breaking oral presentation at 2020 American Academy of Dermatology Annual Meeting by its Asian Partner, Kaken Pharmaceutical, for sofpironium bromide
Feb 20, 2020: Brickell Biotech announces publication of its U.S. phase 2b study results for Sofpironium Bromide in patients with primary axillary hyperhidrosis in the journal of the American Academy of Dermatology
Jan 10, 2020: Brickell Bio’s development partner, Kaken Pharmaceutical, submits New Drug Application for Sofpironium Bromide in Japan for Primary Axillary Hyperhidrosis
Jul 09, 2019: Dermata Therapeutics announces positive results from a phase 1 clinical trial of DMT410, a new topical delivery mechanism for botulinum toxin
Feb 20, 2018: Sofpironium Bromide Demonstrates Promising Potential as a Safe and Effective First-Line Treatment for Primary Axillary Hyperhidrosis (Excessive Underarm Sweating)
Oct 24, 2017: Brickell Biotech Announces Positive Phase 2b Study Results for BBI-4000 (Sofpironium Bromide) in Subjects with Primary Axillary Hyperhidrosis
Feb 27, 2017: TheraVida Announces Publication of Phase 2 Results for THVD-102 in Hyperhidrosis
Oct 03, 2016: THVD-102 Demonstrates Promising Potential as an Orally Administered Treatment for Hyperhidrosis
Mar 07, 2016: BBI-4000 (Sofpironium Bromide) Demonstrates Promising Potential as a Safe and Effective First-line Treatment for Excessive Underarm Sweating
Dec 17, 2015: Brickell Biotech Achieves Statistically Significant and Clinically Meaningful Phase 2b Results for BBI-4000 in Patients with Hyperhidrosis
Sep 24, 2014: Brickell Biotech Announces Positive Preliminary Results of a Pilot Clinical Study of BBI-4000 for the Treatment of Hyperhidrosis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Axillary Hyperhidrosis - Overview
Axillary Hyperhidrosis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Axillary Hyperhidrosis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Axillary Hyperhidrosis - Companies Involved in Therapeutics Development
Brickell Biotech Inc
DelNova Inc
Dermata Therapeutics LLC
Dermavant Sciences Inc
Dermira Inc
Dr. August Wolff GmbH & Co KG Arzneimittel
Medytox Inc
Revance Therapeutics Inc
Axillary Hyperhidrosis - Drug Profiles
(oxybutynin + pilocarpine) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DMT-410 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
glycopyrrolate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
glycopyrronium tosylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nivobotulinumtoxin A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
onabotulinumtoxinA biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ReViVox - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sofpironium bromide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Axillary Hyperhidrosis - Dormant Projects
Axillary Hyperhidrosis - Discontinued Products
Axillary Hyperhidrosis - Product Development Milestones
Featured News & Press Releases
Aug 31, 2020: Brickell Biotech announces issuance of new composition of matter patent on Sofpironium Bromide by the Japanese Patent Office
Jun 15, 2020: Confirmatory phase 3 study of BBI-4000 meet primary endpoint- Announcement at the 119th Annual Meeting of the Japanese Dermatological Association and the 2020 Annual Meeting of American Academy of Dermatology
Jun 15, 2020: Brickell Biotech announces positive Phase 3 pivotal study results for Sofpironium Bromide in Japan released by development partner, Kaken Pharmaceutical
Mar 04, 2020: Brickell Biotech announces late-breaking oral presentation at 2020 American Academy of Dermatology Annual Meeting by its Asian Partner, Kaken Pharmaceutical, for sofpironium bromide
Feb 20, 2020: Brickell Biotech announces publication of its U.S. phase 2b study results for Sofpironium Bromide in patients with primary axillary hyperhidrosis in the journal of the American Academy of Dermatology
Jan 10, 2020: Brickell Bio’s development partner, Kaken Pharmaceutical, submits New Drug Application for Sofpironium Bromide in Japan for Primary Axillary Hyperhidrosis
Jul 09, 2019: Dermata Therapeutics announces positive results from a phase 1 clinical trial of DMT410, a new topical delivery mechanism for botulinum toxin
Feb 20, 2018: Sofpironium Bromide Demonstrates Promising Potential as a Safe and Effective First-Line Treatment for Primary Axillary Hyperhidrosis (Excessive Underarm Sweating)
Oct 24, 2017: Brickell Biotech Announces Positive Phase 2b Study Results for BBI-4000 (Sofpironium Bromide) in Subjects with Primary Axillary Hyperhidrosis
Feb 27, 2017: TheraVida Announces Publication of Phase 2 Results for THVD-102 in Hyperhidrosis
Oct 03, 2016: THVD-102 Demonstrates Promising Potential as an Orally Administered Treatment for Hyperhidrosis
Mar 07, 2016: BBI-4000 (Sofpironium Bromide) Demonstrates Promising Potential as a Safe and Effective First-line Treatment for Excessive Underarm Sweating
Dec 17, 2015: Brickell Biotech Achieves Statistically Significant and Clinically Meaningful Phase 2b Results for BBI-4000 in Patients with Hyperhidrosis
Sep 24, 2014: Brickell Biotech Announces Positive Preliminary Results of a Pilot Clinical Study of BBI-4000 for the Treatment of Hyperhidrosis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development for Axillary Hyperhidrosis, H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Axillary Hyperhidrosis - Pipeline by Brickell Biotech Inc, H2 2020
Axillary Hyperhidrosis - Pipeline by DelNova Inc, H2 2020
Axillary Hyperhidrosis - Pipeline by Dermata Therapeutics LLC, H2 2020
Axillary Hyperhidrosis - Pipeline by Dermavant Sciences Inc, H2 2020
Axillary Hyperhidrosis - Pipeline by Dermira Inc, H2 2020
Axillary Hyperhidrosis - Pipeline by Dr. August Wolff GmbH & Co KG Arzneimittel, H2 2020
Axillary Hyperhidrosis - Pipeline by Medytox Inc, H2 2020
Axillary Hyperhidrosis - Pipeline by Revance Therapeutics Inc, H2 2020
Axillary Hyperhidrosis - Dormant Projects, H2 2020
Axillary Hyperhidrosis - Discontinued Products, H2 2020
Number of Products under Development for Axillary Hyperhidrosis, H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Axillary Hyperhidrosis - Pipeline by Brickell Biotech Inc, H2 2020
Axillary Hyperhidrosis - Pipeline by DelNova Inc, H2 2020
Axillary Hyperhidrosis - Pipeline by Dermata Therapeutics LLC, H2 2020
Axillary Hyperhidrosis - Pipeline by Dermavant Sciences Inc, H2 2020
Axillary Hyperhidrosis - Pipeline by Dermira Inc, H2 2020
Axillary Hyperhidrosis - Pipeline by Dr. August Wolff GmbH & Co KG Arzneimittel, H2 2020
Axillary Hyperhidrosis - Pipeline by Medytox Inc, H2 2020
Axillary Hyperhidrosis - Pipeline by Revance Therapeutics Inc, H2 2020
Axillary Hyperhidrosis - Dormant Projects, H2 2020
Axillary Hyperhidrosis - Discontinued Products, H2 2020
LIST OF FIGURES
Number of Products under Development for Axillary Hyperhidrosis, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Targets, H2 2020
Number of Products by Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020
COMPANIES MENTIONED
Brickell Biotech Inc
DelNova Inc
Dermata Therapeutics LLC
Dermavant Sciences Inc
Dermira Inc
Dr. August Wolff GmbH & Co KG Arzneimittel
Medytox Inc
Revance Therapeutics Inc
Number of Products under Development for Axillary Hyperhidrosis, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Targets, H2 2020
Number of Products by Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020
COMPANIES MENTIONED
Brickell Biotech Inc
DelNova Inc
Dermata Therapeutics LLC
Dermavant Sciences Inc
Dermira Inc
Dr. August Wolff GmbH & Co KG Arzneimittel
Medytox Inc
Revance Therapeutics Inc
